Viking Therapeutics Q3 2026 Earnings: Phase 3 Expansion Widens Net Loss

Viking Therapeutics (NASDAQ: VKTX) reported no revenue for Q3 2026, unchanged from a year earlier, while basic and diluted net loss per share widened to $1.55 from $0.81. Net loss more than doubled to $183.2 million as the company expanded clinical trials, manufacturing and organizational support for its obesity pipeline. A September financing lifted quarter-end cash and short-term investments to $960 million while VK2735 advanced across four Phase 3 trials.

Core Earnings Data

Quarterly operating expenses increased to $187.1 million from $98.6 million. R&D accounted for most of the increase, reflecting planned and ongoing clinical studies, manufacturing, stock-based compensation, employee costs and outside consultants, partly offset by lower preclinical spending.

G&A expense also increased, driven by legal and patent services, consultants, stock-based compensation and employee costs. Total other income of $3.9 million partially offset the operating loss, but it was lower than $7.8 million a year earlier.

VK2735 Phase 3 Development Expanded

Viking’s principal operating progress came from expanding the clinical program for VK2735, its wholly owned GLP-1/GIP dual agonist for obesity.

The injectable VANQUISH program continued on schedule during the quarter. VANQUISH-1 enrolled approximately 4,500 adults with obesity, while VANQUISH-2 enrolled approximately 1,000 adults with obesity and type 2 diabetes. Both studies are evaluating weekly subcutaneous VK2735 over 78 weeks, and Viking expects them to be completed in 2027.

Extension studies are expected to begin in Q1 2027 and will allow treatment to continue for up to another 52 weeks. The VANQUISH-1 extension will also test every-other-week and monthly administration, with extension results anticipated in 2028.

Viking also initiated the oral SUNRISE Phase 3 program. SUNRISE-1 will enroll adults with obesity, while SUNRISE-2 will enroll overweight or obese adults with type 2 diabetes. Each trial is targeting 560 participants and will evaluate once-daily oral doses of 27.5 mg, 35 mg and 55 mg against placebo over 68 weeks.

Maintenance Data Support Less-Frequent Dosing

Part 1 of Viking’s 180-subject VK2735 maintenance study produced evidence supporting less-frequent injectable dosing. After 21 weeks of weekly induction treatment, mean weight loss ranged from approximately 16% to 19%, compared with approximately 0% for placebo.

Participants subsequently moved to every-other-week or monthly dosing for 12 weeks. At Week 33, the every-other-week groups retained 83% to 97% of their initial weight loss, while the monthly groups retained 82% to 90%. Participants switched to placebo retained 61%. An exploratory group that remained on weekly 17.5 mg dosing reached approximately 22% weight loss from baseline at Week 33, without an observed plateau.

Viking has started Part 2 in approximately 195 adults. This study will compare daily oral maintenance doses, monthly and every-other-week injections, and placebo following a 21-week injectable induction period. Results are expected in 2027 and may help determine longer-term dosing strategies for VK2735.

Earlier-Stage Obesity Pipeline

The Phase 1 single ascending dose study of VK3019, Viking’s dual amylin and calcitonin receptor agonist, was nearing completion at the time of the update. The company expects to begin a four-week multiple ascending dose study in Q1 2027.

VK3019 broadens Viking’s obesity pipeline beyond VK2735, but it remains at an early clinical stage. The next study will evaluate safety, tolerability and pharmacokinetics across multiple doses, with changes in body weight included as an exploratory assessment.

Financing Lifted Liquidity as Phase 3 Spending Accelerated

Viking completed concurrent public offerings of common stock and convertible senior notes in September, generating approximately $575 million of gross proceeds and $550 million of net proceeds. As a result, cash, cash equivalents and short-term investments increased to approximately $960 million at September 30 from $706 million at the end of 2025.

The stronger cash position came from external financing rather than operating profitability. The transactions also added convertible-note liabilities, while the number of outstanding common shares increased by about 11% from year-end.

Management said the financing provides resources to conduct multiple Phase 3 trials, advance earlier-stage programs and build infrastructure for a potential VK2735 commercial launch. No specific cash-runway duration was provided.

Risks Investors Need to Watch

• Phase 3 execution: VANQUISH and SUNRISE together comprise four large registration trials. Delays, enrollment issues or results that do not reproduce earlier efficacy and tolerability findings could materially affect the VK2735 program.
• Rapid expense growth: Quarterly R&D expense rose about 85%, while G&A expense more than doubled. Multiple Phase 3 trials, extension studies, manufacturing and commercial preparations create substantial continuing funding requirements.
• Financing and dilution: The September transactions strengthened liquidity but increased convertible-note obligations and the outstanding share count. Additional funding could further affect the company’s capital structure.
• No commercial revenue: Viking remained a pre-commercial biotechnology company with no Q3 revenue. Its financial outlook depends on successful clinical development, regulatory progress and an eventual product launch.

Summary

Viking Therapeutics’ Q3 2026 results reflected a major expansion of its obesity development program rather than commercial performance. Spending increased sharply as injectable and oral VK2735 moved through four Phase 3 trials, while maintenance-dosing data supported further study of less-frequent treatment. The September financing provides substantial liquidity, but investors now need to monitor Phase 3 execution, rising development costs and the capital-structure effects of funding those programs.